2009
Acute phosphate nephropathy
Markowitz GS, Perazella MA. Acute phosphate nephropathy. Kidney International 2009, 76: 1027-1034. PMID: 19675530, DOI: 10.1038/ki.2009.308.Peer-Reviewed Original ResearchConceptsAcute phosphate nephropathyAcute kidney injuryChronic kidney diseasePhosphate nephropathySubsequent chronic renal failureChronic tubular injuryAngiotensin receptor blockersChronic renal failureHigh-risk patientsRenal biopsy findingsClinical-pathological entityAggressive hydrationKidney injuryReceptor blockersBiopsy findingsRenal failureTubular injuryKidney diseasePathological entityRisk factorsFemale genderDistal tubulesEpidemiologic studiesDistal nephronEnzyme inhibitors
2001
Pharmacologic options available to treat symptomatic intradialytic hypotension
Perazella M. Pharmacologic options available to treat symptomatic intradialytic hypotension. American Journal Of Kidney Diseases 2001, 38: s26-s36. PMID: 11602458, DOI: 10.1053/ajkd.2001.28092.Peer-Reviewed Original ResearchConceptsSymptomatic intradialytic hypotensionIntradialytic hypotensionHigh-risk patientsLower blood pressurePharmacologic optionsPharmacologic therapyBlood pressurePatient factorsAvailable therapiesPharmacologic interventionsHypotensionTherapyTreatmentInitial approachMidodrineNephrologistsPatientsSertraline
2000
Are selective COX-2 inhibitors nephrotoxic?
Perazella M, Eras J. Are selective COX-2 inhibitors nephrotoxic? American Journal Of Kidney Diseases 2000, 35: 937-940. PMID: 10793030, DOI: 10.1016/s0272-6386(00)70266-6.Peer-Reviewed Original ResearchConceptsHigh-risk patientsRenal insufficiencySelective cyclooxygenase-2 enzyme inhibitorsSuch high-risk patientsNonsteroidal anti-inflammatory drugsSelective COX-2 inhibitorsChronic renal impairmentChronic renal insufficiencyAcute renal failureAcute renal insufficiencyAdverse gastrointestinal effectsCyclooxygenase-2 enzyme inhibitorsAnti-inflammatory drugsCourse of therapyCOX-2 inhibitorsPain syndromeRenal impairmentRenal failureGastrointestinal effectsNephrotoxic potentialInflammatory diseasesEnzyme inhibitorsPatientsInsufficiencyInhibitors